Connect with us

National

Demise of ‘Don’t Ask’ celebrated, but questions linger

Pentagon, lawmakers herald end of military’s gay ban

Published

on

Defense Secretary Leon Panetta (Blade photo by Michael Key)

Top Pentagon leaders and lawmakers celebrated the end of “Don’t Ask, Don’t Tell” this week as questions about the impact of the law’s repeal persist for gay service members.

Defense Secretary Leon Panetta said during a news conference that the end of “Don’t Ask, Don’t Tell” is “an historic day for the Pentagon and for the nation.”

“As secretary of defense, I am committed to removing all of the barriers that would prevent Americans from serving their country and from rising to the highest level of responsibility that their talents and capabilities warrant,” Panetta said. “These are men and women who put their lives on the line in the defense of this country, and that’s what should matter the most.”

Panetta said more than 97 percent of the 2.3 million men and women in the armed forces have received education and training on handling open service. The training started after President Obama signed repeal legislation in December.

Chairman of the Joint Chiefs of Staff Adm. Mike Mullen, who was likely making his final appearance before the media in his role before stepping down from his position Oct. 1, recalled the testimony he gave before the Senate in February 2010 in favor of repeal.

“I believed then, and I still believe, that it was first and foremost a matter of integrity; that it was fundamentally against everything we stand for as an institution to force people to lie about who they are just to wear a uniform,” Mullen said. “We are better than that. We should be better than that.”

Hours earlier, U.S. senators who were among the 65 who voted for repeal held a separate news conference to commemorate the end of “Don’t Ask, Don’t Tell.”  Sens. Joseph Lieberman (I-Conn.) and Susan Collins (R-Maine), the original co-sponsors of the repeal legislation, were joined by Senate Armed Services Committee Chair Carl Levin (D-Mich.), Mark Udall (D-Colo.), Chris Coons (D-Del.) and Kirsten Gillibrand (D-N.Y.).

Lieberman said the effort to repeal “Don’t Ask, Don’t Tell” in Congress was one of the most satisfying and thrilling experiences he’s had as a senator.

“In our time, I think the front line of the civil rights movement is to protect people in our country from discrimination based on sexual orientation — all the more so when it comes to the United States military, whose mission is to protect our security so we can continue to enjoy the freedom and equal opportunity under law,” Lieberman said.

Sen. Susan Collins (center) with other U.S. senators (Blade photo by Michael Key)

Collins read aloud a postcard she received in July after her committee vote in favor of “Don’t Ask, Don’t Tell” repeal from someone in Afghanistan who signed the note anonymously as “an Army soldier.” The postcard thanks Collins for her vote as a Republican and pledges to repay the vote “with continued professionalism.”

“This touches me so much for two reasons,” Collins said. “One, that this Army soldier deployed in Afghanistan took the time to write to thank me for my leadership. But second, it is so poignant that he couldn’t sign his name. He had to write, ‘an Army soldier,’ and today he can sign his name, and that makes all the difference.”

Amid the celebrations over the end of “Don’t Ask, Don’t Tell” at these news conferences, questions emerged about how to extend greater benefits to LGBT service members.

Only half the senators at the news conference — Udall, Gillibrand and Coons — are co-sponsors of legislation that would repeal the Defense of Marriage Act, which prohibits same-sex marriage. Collins, Lieberman and Levin aren’t co-sponsors of the legislation known as the Respect for Marriage Act.

Collins left the news conference at the start of the question-and-answer period. In response to a question from the Washington Blade, Levin affirmed his support for the Respect for Marriage Act, while Lieberman offered qualified support.

The Connecticut senator said he had issues with the “full faith and credit” portion of the Respect for Marriage Act enabling federal benefits to flow to married gay couples even if they live in a state that doesn’t recognize same-sex marriage.

“I do support it in part — I think we’ve got to celebrate what we’ve done today — I certainly support it in regard to discrimination in federal law based on sexual orientation,” Lieberman said.

During the Pentagon news conference, one reporter asked about possible guards against troops opposed to open service attempting to undermine it by committing acts of harassment or violence against gays.

Panetta said the military has “zero tolerance” for harassment and the command structure in place should address any such behavior.

“My hope is that the command structure operating with … the standard disciplines that are in place will implement those disciplines and will ensure that harassment doesn’t take place and that all behavior is consistent with the discipline and the best interests of our military,” Panetta said.

Some advocates have said the chain of command doesn’t provide sufficient protection against discrimination for gay service members — particularly if the discrimination is coming from a commanding officer — and have called on Obama to sign an executive order barring discrimination in the armed forces on the basis of sexual orientation and gender identity.

Another lingering question is whether military chaplains can officiate at same-sex weddings and if base facilities can be used for such ceremonies in states where same-sex marriage is legal.

A Navy memo dated April 13 affirmed that chaplains could officiate at same-sex weddings and base facilities could be used for this purpose, but this guidance was rescinded after an outcry from social conservatives. Guidance on the matter has yet to be reissued.

Following the Pentagon news conference, Defense Department General Counsel Jeh Johnson took questions from the media, and, in response to a question from the Blade, said such guidance clarifying the rules is forthcoming.

“We are very, very close to having a resolution of that issue,” Johnson said. “It’s something I’ve been working on myself. … We’re pretty much done and there should be something issued to the chaplain community and others very, very soon on that.”

 

Continue Reading
Advertisement

National

VA to start process of covering gender reassignment surgery for trans veterans

Coverage was rejected even during Obama years

Published

on

The Department of Veterans Affairs has become the latest federal government health program to affirm it would begin covering gender reassignment surgery — an option for transgender veterans that was even rejected during the Obama administration.

Randal Noller, a VA spokesperson, said in response to an email inquiry from the Blade the department this summer “will initiate steps to modify rules published in the Code of Federal Regulations (also known as the CFR), to expand VA’s care to transgender Veterans and include gender-affirming surgery.”

“Gender-affirming procedures have been proven effective at mitigating serious health conditions, including suicidality, substance abuse, and dysphoria,” Noller said. “Updating this policy would allow VA to provide transgender and gender diverse Veterans with coordinated, medically necessary, transition-related surgical procedures.”

Noller added the change “would enable a safe, coordinated continuum of care that is Veteran-centric and consistent with VA values of equity and respect for all veterans.” The entire process for implementation, Noller said, can take about two years and includes a period of public comment. 

VA Secretary Denis McDonough first announced the policy change in a speech in Orlando marking the five-year anniversary of the mass shooting at the Pulse nightclub.

Once implemented, the VA would join other federal health care systems in offering coverage for gender reassignment surgery, which previously has included Medicare, Medicaid (other some states, like Iowa, are dubiously claiming exemptions), the Federal Employee Health Benefits programs and the U.S. military health care system as a result of the Biden administration reversing the transgender military ban.

The idea of the VA offering coverage for gender reassignment surgery was first raised during the Obama administration. However, in the lame duck session after former President Trump was elected, the then-Secretary of Veterans Affairs scrapped the idea, citing concerns about appropriate funding.

According to the National Center for Transgender Equality, the estimated number of U.S. veterans who are transgender is more than 134,000, and more than 15,000 transgender people are serving in the military today.

Mara Keisling, executive director of the National Center for Transgender Equality, hailed the change in a statement on Saturday as “another step in the Biden administration’s effort to fight discrimination against transgender people, including our transgender veterans.”

“Every veteran deserves to have access to the health care that they need, and the VA is working to make sure that includes transgender veterans as well,” Keisling said.

Continue Reading

National

HIV research sped development of COVID vaccine

Top NIH official says success in coronavirus will boost AIDS work

Published

on

‘In many ways, the work for the past 25 years that we’ve done in HIV vaccines sped the development of coronavirus vaccines,’ Carl W. Dieffenbach, Ph.D.

Since 1996, Carl W. Dieffenbach, who holds a Ph.D. in biophysics from John Hopkins University, has served as director of the Division of AIDS at the National Institute of Allergies and Infectious Diseases, which is an arm of the U.S. National Institutes of Health or NIH.

In a June 10 interview with the Washington Blade, Dieffenbach gave an update on the extensive, ongoing research into the development of an HIV/AIDS vaccine that he has helped to coordinate for many years, including current human trials for a prospective AIDS vaccine taking place in the U.S., South America, and Africa.

One thing he feels passionate about is a development not widely reported in the media reports about the successful development of the COVID-19 vaccine. According to Dieffenbach, the extensive research into an AIDS vaccine in recent and past years, while not yet successful in yielding an effective AIDS vaccine, helped lay the groundwork for the rapid development of the different versions of a COVID vaccine.

“Because my division runs the largest clinical trials program in the word, we jumped in with both feet to help with coronavirus disease for both vaccines and drugs and things like that,” he said. “And the platforms that were used – the way they are making the coronavirus vaccines – the RNA vaccines with Moderna – were first piloted by NIH and Moderna to try to make an HIV vaccine,” Dieffenbach says.

“So, in many ways, the work for the past 25 years that we’ve done in HIV vaccines sped the development of coronavirus vaccines,” he told the Blade. “And now it’s time to take what we’ve learned from coronavirus and take it back to HIV and start afresh or continue with what we have and build upon from what we have learned.”

Dieffenbach says one reason the development of a COVID vaccine came about before an AIDS vaccine, despite more than 20 years of AIDS vaccine research, is that the HIV virus is far more complex than the coronavirus, especially its ability to infect and remain embedded in the infected person for life. 

“Back in 2007 we had the first hint that an AIDS vaccine might be possible with a study called RV144,” Dieffenbach says. “We spent 10 years trying to replicate that, and we just completed that study – a study called HVTN702. And it showed no efficacy,” he said, meaning it did not work.

“So that was a big disappointment to us,” he says “But in the meantime, we had pushed forward with the J&J [Johnson and Johnson pharmaceutical company] vaccine and are pretty far along. We’ll see what happens. We should know in the next several months whether the N26 version of an AIDS vaccine, and HIV vaccine works or not,” he says. “We’re very close to an answer.”

Washington Blade: Where do things stand in the development of an HIV/AIDS vaccine in light of Dr. Fauci’s statement a few weeks ago that the development of a COVID-19 vaccine could provide a boost to developing an AIDS vaccine?

Carl Dieffenbach: Sure. So, maybe I can start by introducing myself to you as a way of putting this into a context.

So, I’m the director of the Division of AIDS, which is the largest funder of HIV research in the world. And I report directly to Dr. Fauci. So, I’m responsible for all AIDS, all the time. And that is my passion and purpose in life. Part of that is working toward a safe, effective, and durable HIV vaccine, which has been one of the two most challenging questions left in science today. The other is a cure. They are connected in some ways.

So, with that as background, when coronavirus disease came along – because my division runs the largest clinical trials program in the world – we jumped in with both feet to help with coronavirus disease for both vaccines and drugs and things like that. And the platforms that were used – the way they are making the coronavirus vaccines – the RNA vaccines with Moderna were first piloted by NIH and Moderna to try to make an HIV vaccine. So, we’ve being working on that platform with Moderna for several years.

The leadership at Pfizer used to be part of a group at Penn, where we were also working with them. The J&J vaccine – we currently have in two Phase III clinical trials for HIV, one in sub-Saharan Africa, specifically in young women and the other one in the Americas in men who have sex with men and transgender individuals. Both of those Phase IIIs are moving along. The women’s study is fully enrolled. The men’s study was hit hard by COVID, but we worked through and will be fully enrolled by September.

One other vaccine just to talk about is the Oxford vaccine, the AstraZeneca vaccine. That is also using a platform at Oxford University, which has been used for HIV. So, in many ways, the work for the past 25 years that we’ve done in HIV vaccines sped the development of coronavirus vaccines. And now it’s time to take what we’ve learned from coronavirus and take it back to HIV and start afresh or continue with what we have and build upon from where we have learned.

Blade: That’s very interesting. But can we assume, then, from the clinical trials that have taken place for an HIV vaccine that they did not succeed in providing the immunity needed for an effective vaccine? 

Dieffenbach: So, that’s exactly the problem we have. Back in 2007 we had the first hint that an AIDS vaccine might be possible with a study called RV144. We spent 10 years trying to replicate that, and we just completed that study – a study called HVTN702. And it showed no efficacy. So, that was a big disappointment to us. But in the meantime, we had pushed forward with the J&J vaccine and are pretty far along. We’ll see what happens. We should know in the next several months whether the N26 version of an AIDS vaccine, and HIV vaccine works or not. We’re very close to an answer.

Blade: So, the human trials are ongoing.

Dieffenbach: Oh, again – the study in young women in sub-Sahara Africa is fully enrolled. The men’s study will be fully enrolled in September. So, we have fought through the coronavirus epidemic to maintain, to nurse these trials along to make sure with the $100 million or so we’ve invested, that we didn’t want them to go down the drain literally because we lost too many people for follow-up. So, this was a herculean effort that has gone on all the time trying to do the vaccine studies for coronavirus disease, which we were also incredibly successful in.

Blade: Can we assume all of the people participating in the studies were HIV negative?

Dieffenbach: Yes, they’re HIV negative. They are people who are at risk. And also, in South America, for example, the major countries we’re in are Peru and Brazil. And they’ve had a strong research culture with us, going back more than a decade. For example, both of those countries played big roles in our studies of pre-exposure prophylaxis. A study called I-PREX that demonstrated that in men who have sex with men that [a PrEP drug] works well to prevent HIV acquisition in seronegative men who have sex with men.

So, we’ve been there. This is a really good setup for the countries, for the citizens that are in those countries that want to avail themselves to the research that has benefited everybody.

 Blade: Among those who are participating in these ongoing AIDS vaccine trials, can we assume they cannot be taking the PrEP anti-retroviral drugs that have been shown to be highly effective in preventing HIV infection?

Dieffenbach: So, what we’ve done is we – everything is by conversation. So, when somebody who is interested in the study comes in, we talk to them. What is your chief interest in being in this study? And a lot of people want to be in the study because then they can access PrEP. They want to make it easier to get a hold of pre-exposure prophylaxis. They feel that is the best way that they can protect themselves.

So, in that situation, what we do is we take those people and link them to PrEP services where they can easily get PrEP in their community. So, first it’s taking care of those people. Then there are people who really have no interest in PrEP. And we actually counsel them every time they come in for a study. Are you sure you don’t want to access PrEP? And those are the people we then say, if you’re not interested in PrEP, what do you think about participating in a vaccine trial?

Because they’re the ones who have the most freedom of thought. They don’t have an opinion about the vaccine or about PrEP. So, those are the people we’ve been focusing on and enrolling. So, we’ve been very careful to make sure that if people wanted PrEP they not only have access, but they didn’t feel like somehow having to trade something in order to get it. The freedom to join a study should be a free choice. And it shouldn’t be a coercive thing to get PrEP. So, we just took that off the table and said if you’re truly interested in PrEP we can get you PrEP and make sure that was available. 

Blade: So, in that case, if they choose PrEP they would not be in the vaccine trial?

Dieffenbach: You know, it’s interesting that you ask it in that way. Because you have relationships with your community, many of the investigators have reported that people will say, you know I tried PrEP and it wasn’t for me. It made me gaseous. It upset my stomach. I wasn’t myself. I tried it. I couldn’t make it work for me. I want to stop PrEP. Am I still eligible for the [vaccine] study? And the answer is of course. Many people are very happy on PrEP and they come in for visits occasionally and say this is working for me and just have the relationship with the doctors there, so it works. So, again, it’s about maintaining contact with your communities.

Blade: Can you tell a little about what happens next after people become part of an HIV vaccine trial. Do you have to keep in touch with these people, and do they have to get an HIV test periodically?

Dieffenbach: Exactly. So, the vaccine consists of a series of injections. It’s a mixture of vector systems that delivers a series of encoded HIV genes that are specifically designed to induce very broad immunity. There’s a whole computer-based process to design those components of the vaccine to make sure that it has sequence similarities with all the different versions of HIV circulating in the globe. And then at the end there is a protein boost. And we carry this out.

So, about every three to four months people come in. They get a shot. They fill out questionnaires. They give a blood sample. And they’re tested for HIV and are given a boost or a placebo. And they stay in touch with the clinic. They come in and out of the clinic. And the retention is quite high in these situations because people really like having the attention of the clinic available to them. It’s part of the community.

Blade: So, they go to a clinic for all of this?

Dieffenbach: It’s a research clinic. It’s not like a state-run health clinic. It’s a research clinic. Clinic is just a term for where people are seen.

Blade: Are any of these AIDS vaccine trials that are going on taking place in the United States?

Dieffenbach: Yes. So, the study is called Mosaico. And it’s HVTN706. And we have sites throughout the United States as well as South America. But that study is limited to men who have sex with men – the one in the United States.

Blade: Is it broader than just men who have sex with men in other countries?

Dieffenbach: No, so we decided to really focus on specific at-risk populations. So, in the Americas we chose to focus on men who have sex with men and transgender individuals. And sub-Saharan Africa we focused on young women because that is the target of the study population. So, 705 is all women in sub-Saharan Africa. And in the Americas in North and South America it is all men who have sex with men and transgender individuals.

Blade: Can we assume that the researchers that are doing these studies have a sensitivity of LGBTQ people? Is there still an issue where people worry about being outed as being gay or transgender?

Dieffenbach: So, many of the sites that we work with have been part of our system for over 20 years. And so, they are trusted members of the LGBTQ community within their cities and states. And ‘states’ is a literal term where it’s a state in Colombia or Peru or Brazil. And so, it is part of the fabric of the gay community in these places. Just like in San Francisco the San Francisco health clinic and the DCF clinics are part and parcel of everything the community does there.

And so, the lead physician in San Francisco is Susan Buchbinder. She has been a leader in health in this population for over 25 years or actually closer to 30 years at this point. We’re all getting old. Do you know that? So, we have been at this a very long time. And really have tried to build structures that are durable and therefore are reliable to the community. And that’s where we go back to the same groups time after time.

Blade: Have the locations of the vaccine testing sites been released publicly?

Dieffenbach: Yes, all of that is publicly available on clinicaltrials.gov. If you go into clinicaltrials.gov and search HVTN705 or HVTN706 you will get a version of the protocol, all the times it’s been modified, where we are – the protocol. All of that is public knowledge and available to you. HVTN705 is the women’s study. HVTN706 is the men’s study.

Blade: Is there a timeframe for when these latest vaccine studies might be completed?

Dieffenbach: I think within the next several months. We will get an answer out of the women’s study and then the men’s study is probably a year away. We were slowed a little bit because of COVID. We actually had to pause enrollment for several months. But we’re back on track.

Blade: Isn’t there a parallel research effort for an HIV/AIDS cure?

Dieffenbach: Yes, we have a very large program in cure research. It is a lot earlier in the discovery process and so it’s still very ‘researchy.’ And we have a very large program called the Martin Delany Collaboratories for Cure Research. Martin Delany was an activist who really pushed NIH in so many wonderful ways to really take the need for a cure seriously. His argument was a cure is the next logical step after effective anti-retroviral therapy. You cannot stop with one pill once a day. You’ve got to keep going. And he was pretty persistent. And unfortunately, he died several years go and we just thought the best way to honor him, and his memory was to name a program after him.

Editor’s note: Next week, in the second and final installment of his interview with the Blade, Dr. Dieffenbach discusses the progress in research and studies into an HIV/AIDS cure and explains from a scientific standpoint why an HIV vaccine is taking longer to develop than a COVID vaccine.

Continue Reading

National

Louisiana Governor John Bel Edwards vetoes trans youth sports bill

Discrimination is not a Louisiana value, and this bill was a solution in search of a problem that simply does not exist in Louisiana

Published

on

Louisiana Governor John Bel Edwards (D) (Official state portrait)

Washington Blade: LGBTQ News, Politics,…

BATON ROUGE – Louisiana’s Democratic John Bel Edwards announced Tuesday that he has vetoed a measure that would have barred trans girls and women from participating on athletic teams or in sporting events designated for girls or women at elementary, secondary and postsecondary schools. 

The measure, Senate Bill 156 authored by Sen. Beth Mizell titled the ‘the Fairness in Women’s Sports Act,’ in the Governor’s eyes, “was a solution in search of a problem that simply does not exist in Louisiana,” Edwards said in his veto statement;

“As I have said repeatedly when asked about this bill, discrimination is not a Louisiana value, and this bill was a solution in search of a problem that simply does not exist in Louisiana. Even the author of the bill acknowledged throughout the legislative session that there wasn’t a single case where this was an issue. 

Further, it would make life more difficult for transgender children, who are some of the most vulnerable Louisianans when it comes to issues of mental health. We should be looking for more ways to unite rather than divide our citizens. And while there is no issue to be solved by this bill, it does present real problems in that it makes it more likely that NCAA and professional championships, like the 2022 Final Four, would not happen in our state. For these and for other reasons, I have vetoed the bill.”

The Baton Rouge Advocate newspaper’s State House reporter, Blake Paterson, noted that [the law] would have required athletic teams or sporting events for women at public institutions be composed only of “biological females,” or those who presumably were listed as female on their birth certificates.

The measure won Senate approval 29-6 and cleared the House 78-19. Those margins are wide enough to override a governor’s veto, though it’s unclear whether lawmakers will return to Baton Rouge to do so.


“Governor Edwards deserves enormous credit for urging Louisianans to reject the politics of division and to focus on what brings us together, including a shared concern for vulnerable children. As his veto message rightly notes, transgender youth already face huge challenges,” Shannon Minter, the Legal Director for the National Center for Lesbian Rights, (NCLR) told the Blade in an email. “Banning them from school sports would not make any child’s life better or safer, but it would bring discredit and economic hardship to the state, which likely would lose NCAA and professional championships. Governor Edward’s veto message is a model of clarity and compassion. We need more leaders with his courage.”

The ACLU reacted in a tweet saying:

 

Continue Reading
Advertisement
Advertisement

Follow Us @washblade

Sign Up for Blade eBlasts

Popular